Manufacturing News of Note—Merck & Co., Just - Evotech to share specialized biologics space; DBL buys GSK cream line in Bangladesh

A closeup of a stock market ticker
(Pixabay)

>  Merck & Co will pay Seattle-based Just – Evotec Biologics $15 million upfront to use excess capacity at a biologics facility the company is building in Redmond, Washington. Story

> GBA Group Pharma has doubled the size of its clinical supply facilities in Vienna ahead of Brexit, it says. Release

> DBL Pharmaceuticals says it has a deal to acquire the cream and ointment manufacturing line of GlaxoSmithKline Bangladesh with plans of reintroducing the products that GSK made there before exiting the country. Story

> Helixmith Co. and Genopis say they will launch a contract manufacturing operation to manufacture plasmid DNA for clients. Release

> Medivant Health is building a 33,000-square-foot generic drug manufacturing facility in Chandler, Arizona, to address drug shortages. Story

Suggested Articles

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.

Branded drug sales in China could suffer in the short term as marketing activities for new meds are limited to reduce the risk of contagion.

Korean CDMO Samsung Biologics is expanding and China API maker WuXi STA opened a 30,000-square-foot oligonucleotide manufacturing facility.